Fund 3
Vesalius Biocapital III

This fund, launched in May 2017 and finally closed in May 2019, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

€120 million of commitments secured

The fund secured over €120 million of commitments; final closing took place in May 2019.



News for Vesalius Biocapital Fund 3

Tonic App raises 3.5 million euros
read more
Mecuris GmbH: Best MedTech Startup
read more
Forendo: Phase 1b Proof
read more